These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 8843205)
1. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. Welles SL; Jackson JB; Yen-Lieberman B; Demeter L; Japour AJ; Smeaton LM; Johnson VA; Kuritzkes DR; D'Aquila RT; Reichelderfer PA; Richman DD; Reichman R; Fischl M; Dolin R; Coombs RW; Kahn JO; McLaren C; Todd J; Kwok S; Crumpacker CS J Infect Dis; 1996 Oct; 174(4):696-703. PubMed ID: 8843205 [TBL] [Abstract][Full Text] [Related]
2. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. Coombs RW; Welles SL; Hooper C; Reichelderfer PS; D'Aquila RT; Japour AJ; Johnson VA; Kuritzkes DR; Richman DD; Kwok S; Todd J; Jackson JB; DeGruttola V; Crumpacker CS; Kahn J J Infect Dis; 1996 Oct; 174(4):704-12. PubMed ID: 8843206 [TBL] [Abstract][Full Text] [Related]
3. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. O'Brien WA; Hartigan PM; Daar ES; Simberkoff MS; Hamilton JD Ann Intern Med; 1997 Jun; 126(12):939-45. PubMed ID: 9182470 [TBL] [Abstract][Full Text] [Related]
4. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144 [TBL] [Abstract][Full Text] [Related]
5. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. D'Aquila RT; Johnson VA; Welles SL; Japour AJ; Kuritzkes DR; DeGruttola V; Reichelderfer PS; Coombs RW; Crumpacker CS; Kahn JO; Richman DD Ann Intern Med; 1995 Mar; 122(6):401-8. PubMed ID: 7856987 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. Tierney C; Lathey JL; Christopherson C; Bettendorf DM; D'Aquila RT; Hammer SM; Katzenstein DA J Infect Dis; 2003 Jan; 187(1):144-8. PubMed ID: 12508159 [TBL] [Abstract][Full Text] [Related]
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227 [TBL] [Abstract][Full Text] [Related]
8. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection. Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281 [TBL] [Abstract][Full Text] [Related]
9. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine. Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824 [TBL] [Abstract][Full Text] [Related]
10. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Sperling RS; Shapiro DE; Coombs RW; Todd JA; Herman SA; McSherry GD; O'Sullivan MJ; Van Dyke RB; Jimenez E; Rouzioux C; Flynn PM; Sullivan JL N Engl J Med; 1996 Nov; 335(22):1621-9. PubMed ID: 8965861 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group. Japour AJ; Welles S; D'Aquila RT; Johnson VA; Richman DD; Coombs RW; Reichelderfer PS; Kahn JO; Crumpacker CS; Kuritzkes DR J Infect Dis; 1995 May; 171(5):1172-9. PubMed ID: 7538548 [TBL] [Abstract][Full Text] [Related]
12. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272 [TBL] [Abstract][Full Text] [Related]
13. Predictive value of HIV-1 RNA detection in plasma by branched DNA assay during long-term zidovudine therapy. Cotte L; Trabaud MA; Rougier P; Bailly F; Chapuis F; Trepo C Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):639-45. PubMed ID: 8894571 [TBL] [Abstract][Full Text] [Related]
14. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331 [TBL] [Abstract][Full Text] [Related]
15. Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection? Arduino JM; Fischl MA; Stanley K; Collier AC; Spiegelman D AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1099-105. PubMed ID: 11522179 [TBL] [Abstract][Full Text] [Related]
16. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine. Opravil M; Hill AM; DeMasi R; Dawson D Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134 [TBL] [Abstract][Full Text] [Related]
17. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. Dykes C; Najjar J; Bosch RJ; Wantman M; Furtado M; Hart S; Hammer SM; Demeter LM J Infect Dis; 2004 Mar; 189(6):1091-6. PubMed ID: 14999613 [TBL] [Abstract][Full Text] [Related]
18. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. Fiscus SA; Hughes MD; Lathey JL; Pi T; Jackson B; Rasheed S; Elbeik T; Reichman R; Japour A; Byington R; Scott W; Griffith BP; Katzenstein DA; Hammer SM J Infect Dis; 1998 Mar; 177(3):625-33. PubMed ID: 9498441 [TBL] [Abstract][Full Text] [Related]
19. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. Schapiro JM; Lawrence J; Speck R; Winters MA; Efron B; Coombs RW; Collier AC; Merigan TC J Infect Dis; 1999 Jan; 179(1):249-53. PubMed ID: 9841849 [TBL] [Abstract][Full Text] [Related]
20. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. Mofenson LM; Lambert JS; Stiehm ER; Bethel J; Meyer WA; Whitehouse J; Moye J; Reichelderfer P; Harris DR; Fowler MG; Mathieson BJ; Nemo GJ N Engl J Med; 1999 Aug; 341(6):385-93. PubMed ID: 10432323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]